Press release
Investigation announced for Investors in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
An investigation for investors in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) shares over potential securities laws violations.
Investors who purchased shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by BioMarin Pharmaceutical Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
San Rafael, CA BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. BioMarin Pharmaceutical Inc. reported that its annual Total Revenue rose from over $1.7 billion in 2019 to over $1.86 billion in 2020, and that its Net Loss of $23.84 million in 2019 turned into a Net Income of $859.1 million in 2020.
On September 5, 2021, BioMarin Pharmaceutical Inc announced "that the U.S Food and Drug Administration (FDA) placed a clinical hold on the BMN 307 Phearless Phase 1/2 study", which "is evaluating BMN 307, an investigational AAV5-phenylalanine hydroxylase (PAH) gene therapy, in adults with phenylketonuria (PKU)." BioMarin advised investors that "[t]he FDA's clinical hold was based on interim safety findings from a pre-clinical, non-GLP pharmacology study."
Shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) declined from $85.28 per share on September 1, 2021, to $76.00 per share on September 15, 2021.
Those who purchased shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) here
News-ID: 2394818 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for BioMarin
Mucopolysaccharidosis Market to Witness Growth by 2032 | BioMarin, Takeda Pharma …
DelveInsight's "Mucopolysaccharidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Mucopolysaccharidosis, historical and forecasted epidemiology, and the Mucopolysaccharidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The Mucopolysaccharidosis market report provides current treatment practices, emerging drugs, the market share of individual therapies, and the current and forecasted Mucopolysaccharidosis market size from 2019 to 2032, segmented by seven major…
Phenylketnuria Treatment Market Future Business Overview 2022-2028 | BioMarin Ph …
Coherent Market Insights has released a new research study on the "Phenylketnuria Treatment Market" which aims to provide a thorough examination of the factors influencing global business introduction and outlook. The Global Phenylketnuria Treatment Market Report detailed information and overview highlight the most recent trends in various regions. Leading market participants will benefit from the trading insights provided in this report. The Phenylketnuria Treatment Market research report is an intelligence…
Lawsuit filed for Investors in shares of BioMarin Pharmaceutical Inc. (NASDAQ: B …
An investor, who purchased shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), filed a lawsuit over alleged violations of Federal Securities Laws by BioMarin Pharmaceutical Inc.
Investors who purchased shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) have certain options and for certain investors are short and strict deadlines running. Deadline: November 24, 2020. NASDAQ: BMRN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Based on BioMarin Pharmaceutical…
Global Amifampridine market:Competitive Landscape & Key Player Tactics|Unichem, …
Los Angeles, United State: The report is a compilation of comprehensive research studies on various aspects of the global Amifampridine Market. With accurate data and highly authentic information, it makes a brilliant attempt to provide a real, transparent picture of current and future situations of the global Amifampridine market. Market participants can use this powerful tool when creating effective business plans or making important changes to their strategies. The report…
Mucopolysaccharidosis (MPS) Treatment Market Demand and Improvement Analysis 201 …
A market study presented by FMI' Mucopolysaccharidosis Treatment Market: Global Industry Analysis 2014-2018 and Opportunity Assessment 2019-2029,' explains the significant factors influencing the current market structure.
According to research, the mucopolysaccharidosis treatment is still emerging, and different geographies have implemented standard treatment options for the condition. However, there is no universally accepted treatment pattern for mucopolysaccharidosis. Mucopolysaccharidosis falls under rare diseases, which is a complex, diverse, constantly evolving field, and there…
Global Hemophilia Gene Therapy Market 2018 - Bioverativ, Shire PLC, BioMarin, un …
Accord Market, recently published a detailed market research study focused on the “Hemophilia Gene Therapy Market” across the global, regional and country level. The report provides 360° analysis of “Hemophilia Gene Therapy Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Hemophilia Gene…
